IRL 2500

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

IRL 2500 是内皮素受体的有效拮抗剂。 IRL 2500 在大鼠体内抑制 ETB 受体介导的血压升高和肾血管阻力。

IRL 2500 is an effective antagonist of the Endothelin receptor. IRL 2500 suppresses ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo. IRL 2500 displays (IC50:1.3 and 94 nM for ETB and ETA receptors, respectively).(In Vivo):In the anesthetized rat, IRL 2500 (10 mg/kg; i.v.) decreases the IRL 1620-mediated enhances renal vascular resistance. IRL 2500 suppresses the initial transient reduction in mean arterial pressure induced by IRL 1620. IRL 2500 (10 mg/kg; i.v.) pre-treatment reduces the initial vasodepressor response to endothelin-1 and IRL 1620 without altering the secondary and sustained pressor response.

——

IRL 2500 (intravenous?injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat.IRL 2500 (intravenous?injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists.

——

Others

Other Targets

EGFR

——

——

169545-27-1

573.693

C36H35N3O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (174.31 mM)

CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1

——

(-20℃)

With Ice Pack

≥ 2 years